Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Corteva Inc.'s published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $8.0B | |
|---|---|---|
| Shares out | 667.2M | |
| P/E (forward) | 19.1x | |
| Dividend | $0.13 (1.16%) | |
| Volume | 14,482,667 | |
| Beta | 0.58 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $15.66B | $17.46B | $17.23B | $16.91B | $17.40B | +2.7% |
| Gross profit | $6.44B | $7.02B | $17.23B | $7.38B | $8.23B | +6.3% |
| Operating income | $2.38B | $1.51B | $941.0M | $1.51B | $1.87B | -5.8% |
| Net income | $1.76B | $1.15B | $735.0M | $907.0M | $1.09B | -11.2% |
| EPS (diluted) | $2.37 | $1.58 | $1.03 | $1.30 | $1.60 | -9.4% |
| EBITDA | $3.62B | $2.73B | $941.0M | $2.74B | $3.07B | -4.0% |
| R&D | $1.19B | $1.22B | $1.34B | $1.40B | $1.47B | +5.6% |
| SG&A | $3.21B | $3.17B | $3.18B | $3.20B | $3.49B | +2.1% |
Recent company headlines from major financial publishers.
Corteva executes on its core operational strategy: Seed segment trait out-licensing continues tracking three years ahead of plan, offsetting broader crop price softening. Crop Protection new patented products touch $2.0B in FY2026, neutralizing mid-single-digit price declines in legacy chemistries. Latin American growth moderates to low-single-digit rates due to tight farmer credit. Cash generation remains robust, funding steady share repurchases and balance sheet health.
Proprietary seed trait licensing expands ahead of schedule across third-party seed networks, driving substantial margin expansion. Patented crop protection molecules and biologicals exceed commercial launch targets, capturing market share from distressed commodity competitors. Brazilian safrinha corn planted area expands briskly, lifting Latin American revenue growth above historical trend and driving diluted EPS to the high end of analyst estimates.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 5.5% | $56.4 | $58.6 | $61.2 | $64.2 | $67.7 |
| 6.0% | $52.0 | $53.6 | $55.5 | $57.6 | $60.1 |
| 6.5% | $48.4 | $49.7 | $51.7 | $52.7 | $54.6 |
| 7.0% | $45.4 | $46.5 | $47.6 | $48.9 | $50.3 |
| 7.5% | $43.0 | $43.8 | $44.7 | $45.7 | $46.8 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
